Rhiannan Hardwick, PhD

My research focused on the effect of nonalcoholic fatty liver disease (NAFLD) on the expression and function of hepatic drug metabolizing enzymes and transporters. Using both human samples and rodent models, I identified alterations in the function of specific enzymes and efflux transporters at the most severe stage of NAFLD, nonalcoholic steatohepatitis (NASH). My dissertation studies revealed that NASH increases the expression of sinusoidal efflux transporters and alters the localization of a specific canalicular efflux transporter which together lead to diminished biliary excretion and increased plasma retention of specific drugs. My dissertation studies also demonstrated that this shift in drug disposition as a result of NASH alters the toxicity profile of xenobiotics. My advise to incoming students would be not to be afraid to apply for funding sources and awards outside of the University of Arizona. There are several fellowships available for graduate students, you only need to look. Also, be active in seeking out collaborations with fellow students while you are at the University of Arizona. Those around you will one day become your professional colleagues so start forging great relationships now. I am currently an NIEHS Postdoctoral Trainee in the Curriculum in Toxicology at the University of North Carolina at Chapel Hill. I am working in the laboratory of Dr. Kim Brouwer which focuses on hepatic drug transport mechanisms and pharmacokinetics.
Pharmacology and Toxicology
Pharmacology and Toxicology
NIEHS Postdoctoral Trainee, Curriculum in Toxicology at The University of North Carolina at Chapel Hill
Dissertation Title: 
“NASH Alters Drug Metabolizing Enzyme and Transporter Expression Resulting in Significant Consequences for Pharmaceutical Disposition and Toxicity"
Honors and Achievements: 
1. Mountain West Society of Toxicology Student Travel Award, 2011.
2. NIEHS Travel Award, 2011-12.
3. American Foundation for Pharmaceutical Education, Pre Doctoral Fellowship (AFPE), 2011-12.
4. Graduate Track Awards: Outstanding Research, 2012-13..
5. SOT Award, First Place, Drug Discovery Toxicology Specialty Section, and Honorable Mention, Carl C. Smith Mechanisms Specialty Section, 2012.
1. Hardwick, R.N., Fisher, C.D., Canet, M.J., Lake, A.D., Cherrington, N.J. Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 28: 2293-2301. (PMID: 20805291) 2010.
2. Hardwick, R.N., Fisher, C.D., Canet, M.J., Scheffer, G.L., Cherrington, N.J. Variations in ABC Transporter Regulation During the Progression of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 39:2395-2402 (PMID: 21878559) 2011.
3. Hardwick, R.N., Fisher, C.D., Street, S.M., Canet, M.J., Cherrington, N.J. Molecular Mechanism of Altered Ezetimibe Disposition in Nonalcoholic Steatohepatitis. Drug Metabolism and Disposition, 40:450-460 (PMID: 22112382) 2012.
4. Druwe, I.L., Hardwick, R., Sanchez Soira, P., Camenisch, T.D. and R.R. Vaillancourt (2012). Arsenite Activates NF-B Through Induction of C-Reactive Protein. Toxicol. Appl. Pharm. 261:263-70.
5. Canet MJ, Hardwick RN, Lake AD, Kopplin MJ, Scheffer GL, Klimecki WT, Gandolfi AJ, Cherrington NJ. Altered Arsenic Disposition in Experimental Nonalcoholic Fatty Liver Disease. Drug Metab. Disp 40:1817-1824, 2012.
Career Type: